Literature DB >> 8707741

Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters.

A Bach1, H Schmidt, B Böttiger, B Schreiber, H Böhrer, J Motsch, E Martin, H G Sonntag.   

Abstract

We determined how long antiseptic impregnation with silver sulphadiazine and chlorhexidine (SCC) on polyurethane central venous double- or triple-lumen catheters is retained in vivo. A total of 116 antiseptic catheters were tested for antibacterial activity in an in-vitro bioassay after various periods of iv catheterization. Segments from the subcutaneous (sc) and intravenous (iv) portions of the catheters were cultured. The results of test antiseptic catheters were compared with those from 117 noncoated control (c) catheters. Retention of antibacterial activity followed an exponential curve and lasted for up to 520 h after catheter insertion. Significant differences (P = 0.0001) between SSC and C catheters were noticed with regard to the quantitative level of bacterial colonization (SSC-sc 87 +/- 34 vs C-sc 584 +/- 122; SSC-iv 52 +/- 17 vs C-iv 286 +/- 57; all values are given as mean cfu +/- S.E.M.), and the frequency of bacterial colonization (SSC-sc 20.7% vs C-sc 38.5%, P = 0.0047; SSC-iv 18.1% vs C-iv 30.8%, P = 0.0361). There was no significant difference between the incidence of catheter-related bacteraemia in the test (n = 0) and control groups (n = 3) (P = 0.2573). Further prospective studies are required to delineate the role of antiseptic catheters in preventing catheter-related infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707741     DOI: 10.1093/jac/37.2.315

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  The relationship between methodological trial quality and the effects of impregnated central venous catheters.

Authors:  Christine Geffers; Irina Zuschneid; Tim Eckmanns; Henning Rüden; Petra Gastmeier
Journal:  Intensive Care Med       Date:  2003-02-08       Impact factor: 17.440

Review 2.  Infections associated with medical devices: pathogenesis, management and prophylaxis.

Authors:  Christof von Eiff; Bernd Jansen; Wolfgang Kohnen; Karsten Becker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Anti-infective-treated central venous catheters: a systematic review of randomized controlled trials.

Authors:  B S Niël-Weise; T Stijnen; P J van den Broek
Journal:  Intensive Care Med       Date:  2007-10-17       Impact factor: 17.440

4.  Impact of chlorhexidine-silver sulfadiazine-impregnated central venous catheters on in vitro quantitation of catheter-associated bacteria.

Authors:  A Bach
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

5.  Clinical and Regulatory Considerations for Central Venous Catheters for Hemodialysis.

Authors:  Douglas M Silverstein; Scott O Trerotola; Timothy Clark; Garth James; Wing Ng; Amy Dwyer; Marius C Florescu; Roman Shingarev; Stephen R Ash
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-11       Impact factor: 8.237

6.  Antimicrobial impregnated catheters in the prevention of catheter-related bloodstream infection in hospitalized patients.

Authors:  Sarah K Wassil; Catherine M Crill; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

7.  Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo.

Authors:  S Bassetti; J Hu; R B D'Agostino; R J Sherertz
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

8.  Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients--a double-blind, randomised, prospective, controlled trial.

Authors:  Torben Ostendorf; Andrea Meinhold; Christoph Harter; Hans Salwender; Gerlinde Egerer; Heinrich K Geiss; Antony D Ho; Hartmut Goldschmidt
Journal:  Support Care Cancer       Date:  2005-04-16       Impact factor: 3.603

Review 9.  New technologies to prevent intravascular catheter-related bloodstream infections.

Authors:  L A Mermel
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

10.  Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial.

Authors:  Christian Brun-Buisson; Françoise Doyon; Jean-Pierre Sollet; Jean-François Cochard; Yves Cohen; Gérard Nitenberg
Journal:  Intensive Care Med       Date:  2004-04-02       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.